期刊文献+

新型肝癌标志CA125及其靶向毒素在肝癌生物治疗中的作用研究 被引量:7

Targeted therapy of hepatocarcinoma by a novel CA125-targeted immunotoxin
下载PDF
导出
摘要 目的:对实验室已构建的新型免疫毒素IAB-TAT-BH3在肝癌靶向治疗中的作用进行初步评价。方法:首先通过免疫组化技术对人肝癌组织芯片中CA125的表达进行检测,同时利用RT-PCR、Western blot和流式细胞术从RNA和蛋白水平对肝癌细胞中CA125的表达进行系统分析;然后通过Western blot和流式细胞术(Flow cytometry,FCM)检测免疫毒素IABTAT-BH3与肝癌细胞株SMMC-7721的结合能力,最后采用MTT法检测其对于SMMC-7721的靶向杀伤作用。结果:CA125在人类肝癌组织芯片和肝癌细胞株SMMC-7721中呈现高表达;免疫毒素IAB-TAT-BH3对于SMMC-7721具有良好的结合能力,且与两种对照免疫毒素相比,具有更强的细胞杀伤作用,IC50值约0.3μmol/L。结论:膜蛋白CA125是潜在的肝癌分子靶标,靶向CA125的新型免疫毒素IAB-TAT-BH3在体外对肝癌细胞具有一定的特异性杀伤作用,在肝癌靶向治疗上具有潜在的应用前景。 Objective:To appraise the effect of novel immunotoxin IAB-TAT-BH3 which was constructed by our lab in hepato- carcinoma targeted therapy. Methods: First, a human liver carcinoma tissue array was used to investigate the expression of CA125 by immunohistochemistry. Then expression of CA125 in different hepatocarcinoma cells was measured by RT-PCR, Western blot and Flow cytometry. Finally, the binding of the immunotoxin to liver cancer cell SMMC-7721 was detected by Western blot and Flow cytometry and the cytotoxicity of 1AB-TAT-BH3 on SMMC-7721 was further appraised by MTT. Results: CA125 was highly expressed in most human liver carcinoma tissues and SMMC-7721 cells; the immunotoxin IAB-TAT-BH3 could specifically binding to SMMC-7721 cells and the IC50 of IAB-TAT-BH3 to this cell line was about 0.3 p, mol/L which is much better than the other two control immunotoxins. Conclusion: The membrane protein CA125 has potential to be a novel marker of hepatocarcinoma. The novel immunotoxin lAB-TAT- BH3 which can target to CA125 can specifically inhibit the proliferation of liver cancer cells in vitro, has great potential in hepatocawi- noma targeted therapy.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2014年第3期342-346,共5页 Chinese Journal of Immunology
基金 上海市科委生物医药领域重点科技攻关专项(074319104)资助
关键词 CA125 分子靶标 肝癌 靶向治疗 CA125 Molecular target Hepatocarcinoma Targeted therapy
  • 相关文献

参考文献13

  • 1王媛媛,韩红辉,杜冰,钱旻.一种新型肝癌免疫毒素的表达、纯化及初步鉴定[J].现代免疫学,2008,28(2):110-115. 被引量:11
  • 2金思思,吴金明.原发性肝细胞癌的肿瘤标志物[J].医学新知,2008,18(4):222-225. 被引量:2
  • 3Lorenza Rimassa, Armando Santoro. The present and the future landscape of treatment of advanced hepatocellular carcinoma [J] . Digest Dis, 2010 ,42 (S3) : S273-S280.
  • 4Osamu Kaneko, Lucy Gong,Jingli Zhang,et al. A binding domain on mesothelin for CAI25/MUCI6 [J]. J Bioi Chern, 2009,284 (6) : 3739-3749.
  • 5Xiang X, Feng M, Felder M ,et al, HNI25:A novel immunoadbesin targeting MUCI6 with potential for cancer therapy [J]. J Cancer, 2011,2:280-291.
  • 6Haridas D, Chakraborty S, Ponnusamy MP, et al. Pathobiological implications of MUCl6 expression in pancreatic cancer [J]. PloS One, 2011 ,6( 10) :e26839.
  • 7Lakshmanan I, Ponnusamy MP, Das S, et al, MUCI6 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells [J]. Oncogene, 2012,31 (7) : 805-817.
  • 8Houda Bouanene, Abdelhedi Miled. Conflicting views on the molecular structure of the cancer antigen CA125/MUCI6 [J]. Dis Markers, 2010 ,28: 385-394.
  • 9Tang Z, Feng M, Gao W, et al, A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface [J]. Mol Cancer Ther, 2013, 12( 4) : 416426.
  • 10Mitchell Ho, Tapan K Bera, Mark C Willingham, et al. Mesothelin expression in human lung cancer [J]. Clin Cancer Res, 2007,13(5): 1571-1575.

二级参考文献17

  • 1JoannaW.Ho,RonnieT.Poon,CindyS.Tong,SheungTatFan.Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2004,10(14):2014-2018. 被引量:6
  • 2吴淼,杜冰,汪磊,周忠良,钱旻,于静.肝癌特异性黏附肽的鉴定和分析[J].现代免疫学,2006,26(2):143-146. 被引量:2
  • 3谢咏梅,严律南,魏兵,郭梅梅,唐承薇.原发性肝癌患者肿瘤组织生长抑素受体表达与血AFP水平的相关性[J].癌症,2007,26(7):688-692. 被引量:6
  • 4[1]Schwartz M,Roayaie S,Konstadoulakis M.Strategies for the management of hepatocellular carcinoma[J].Nat Clin Pract Oncol,2007,4(7):424-432.
  • 5[2]Pastan I,Hassan R,FitzGerald DJ,et al.Immunotoxin treatment of cancer[J].Annu Rev Med,2007,58:221-237.
  • 6[5]Du B,Qian M,Zhou Z,et al.In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library[J].Biochem Biophys Res Commun,2006,342(3):956-962.
  • 7[6]Wu M,Du B,Wang L,et al.A Liver-tumor adhere peptide from the phage radom peptide library[J].Chin Cancer Res,2006,18(4):241-245.
  • 8[7]Park SC,Kim JY,Shin SO,et al.Investigation of toroidal pore and oligomerization by melittin using transmission electron microscopy[J].Biochem Biophys Res Commun,2006,343(1):222-228.
  • 9[8]Son DJ,Lee JW,Lee YH,et al.Therapeutic application of anti-arthritis,pain-releasing,and anti-cancer effects of bee venom and its constituent compounds[J].Pharmacol Ther,2007,115(2):246-270.
  • 10[9]Chu ST,Cheng HH,Huang CJ,et al.Phospholipase A2-independent Ca2+entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells[J].Life Sci,2007,80(4):364-369.

共引文献11

同被引文献66

  • 1黄大庆,曾波,牟忠亮,汪培英,周石.肝动脉灌注化疗栓塞联合DSA引导下射频消融术治疗肝癌的疗效[J].中国老年学杂志,2014,34(6):1644-1646. 被引量:5
  • 2Pingsheng F,Tengyue Z,Qiang H,et al.Basic and Clinical Research on the Therapeutic Effect of Intervention in Primary Liver Cancer by Targeted Intra-Arterial Verapamil Infusion[J].Cell biochemistry and biophysics,2012,62(1):59-67.
  • 3Ji Z.,Lin G.,Lu Q,et al.Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system[J].Journal of Colloid and Interface Science,2012,365(1):143-149.
  • 4Liu M.,Li Z.H,Xu F.J,et al.An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy[J].Biomaterials,2012,33(7):2240-2250.
  • 5Wang J.L.,Tang G.P.,Shen J,et al.A gene nanocomplex conjugated with monoclonal antibodies for targeted therapy of hepatocellular carcinoma[J].Biomaterials,2012,33(18):4597-4607.
  • 6Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69-90.
  • 7Wang D, Fan Z, Liu F, et al. Hsa-miR-21 and Hsa-miR-29 in tissue as potential diagnostic and prognostic biomarkers for gastric cancer [ J ]. Cell Physiol Biochem ,2015,37 (4) : 1454-1462.
  • 8Miyazaki T, Ikeda K, Sato W, et al. MicroRNA library-based functional screening identified androgen-sensitive miR-216a as a player in bicalutamide resistance in prostate cancer [ J ]. J Clin Med,2015,4(10) :1853-1865.
  • 9Fujiwara N, Inoue J, Kawano T, et al. miR-634 activates the mitochondrial apoptosis pathway and enhances chemotherapy- induced cytotoxieity [ J]. Cancer Res ,2015,75 ( 18 ) :3890-3901.
  • 10Cong J, Liu R, Wang X,et al. MiR-634 decreases cell proliferation and induces apoptosis by targeting mTOR signaling pathway in cervical cancer cells [ J]. Artif Cells Nanomed Bioteehnol,2015, 14:1-8.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部